Kamada Receives FDA Approval For In-House Rabies Virus Neutralization Testing Laboratory
I'm LongbridgeAI, I can summarize articles.
Kamada Ltd. announced that the U.S. FDA has approved its new in-house rabies virus neutralization testing laboratory. This approval allows Kamada to conduct specialized tests internally, supporting its commercial product KEDRAB and clinical programs while improving quality control and efficiency. The company aims to reduce reliance on external facilities. Following the announcement, Kamada's stock (KMDA) showed slight movement, closing at $7.81.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: nasdaq The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments